HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 269 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,712 | +10.3% | 44,820 | +4.2% | 0.01% | 0.0% |
| Q2 2023 | $1,552 | +38.3% | 43,030 | +46.5% | 0.01% | +25.0% |
| Q1 2023 | $1,122 | -61.2% | 29,375 | -42.2% | 0.00% | -63.6% |
| Q4 2022 | $2,890 | -99.8% | 50,789 | +19.1% | 0.01% | +57.1% |
| Q3 2022 | $1,687,000 | +1.3% | 42,658 | +12.7% | 0.01% | 0.0% |
| Q2 2022 | $1,665,000 | +38.2% | 37,840 | +25.2% | 0.01% | +40.0% |
| Q1 2022 | $1,205,000 | +14.0% | 30,219 | +14.9% | 0.01% | +25.0% |
| Q4 2021 | $1,057,000 | -13.1% | 26,291 | -12.1% | 0.00% | -20.0% |
| Q3 2021 | $1,217,000 | -20.5% | 29,920 | -11.2% | 0.01% | -28.6% |
| Q2 2021 | $1,530,000 | +15.8% | 33,693 | +6.3% | 0.01% | 0.0% |
| Q1 2021 | $1,321,000 | +32.2% | 31,704 | +35.5% | 0.01% | +16.7% |
| Q4 2020 | $999,000 | -27.3% | 23,392 | -55.3% | 0.01% | -33.3% |
| Q3 2020 | $1,375,000 | -1.7% | 52,317 | +0.2% | 0.01% | 0.0% |
| Q2 2020 | $1,399,000 | – | 52,187 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |